Last updated on January 2020

M7824 in People With Recurrent Respiratory Papillomatosis

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Human Papilloma Virus | Laryngeal Papilloma | Respiratory Papillomatosis | Recurrent | Recurrent Respiratory Papillomatosis
  • Age: Between 18 - 99 Years
  • Gender: Male or Female


RRP criteria:

  • Histological diagnosis of RRP confirmed by pathology report from a CLIA-certified laboratory.
  • One of the following:
  • A Derkay anatomic score of 10 or greater and a history of two or more endoscopic interventions in the last 12 months for control of RRP.
  • Pulmonary RRP with pulmonary disease that is measurable by computed tomography scan and evaluated by RECIST Criteria.
  • Tracheal involvement with RRP that has required either two or more endoscopic interventions in the last 12 months or a tracheostomy.
  • Greater than or equal to 18 years of age.
  • Able to understand and sign the Informed Consent Document.
  • Clinical performance status of ECOG 0 or1.
  • Willing to undergo endoscopic evaluation with biopsies in compliance with this protocol.
  • No systemic therapy for RRP for at least 3 half-lives of the prior drug(s).
  • Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to first dose:
  • WBC > 2000/ microliter
  • Neutrophils > 1000/ microliter
  • Platelets > 75 x10(3)/ microliter
  • Hemoglobin > 9.0 g/dL
  • Serum Creatinine < 1.5 x ULN OR eGFR > 30 mL/min (measured or calculated using the MDRD equation).
  • AST/ALTless than or equal to 2.5 x ULN
  • Total Bilirubin :S 1.5 x ULN
  • Sexually active subjects (men and women) of reproductive potential must agree to use two methods of contraception: one highly effective and one other effective method throughout M7824 treatment and for at least 120 days after M7824 treatment. Highly Effective Methods are defined as: Intrauterine device (IUD), hormonal (birth control pills, injections, implants), tubal ligation and partner s vasectomy; Other are defined as: latex condom, diaphragm and cervical cap.
  • Seronegative for HIV antibody. The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune function and thus are likely less responsive to the experimental treatment.
  • Seronegative for hepatitis B antigen, positive hepatitis B tests can be further evaluated by confirmatory tests (Hep B DNA Quant, HBV Viral Load), and if confirmatory tests are negative, the patient can be enrolled.
  • Seronegative for hepatitis C antibody unless antigen negative. If hepatitis C antibody test is positive, then patients must be tested for the presence of antigen by Hep C RNA Quant, HCV Viral Load and be HCV RNA negative.


  • Any severe acute or chronic medical or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior, liver disease, lung disease (with the exception of what is specified in inclusion criteria) , or laboratory abnormalities that, in the opinion of the investigators, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results and in the judgment of the investigator, would make the patient inappropriate for entry into this study. Patients with mild to moderate asthma or chronic obstructive pulmonary disease (COPD) well controlled with oral or inhaled medications are permitted to enroll.
  • Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, or psoriasis not requiring systemic treatment, are permitted to enroll.
  • Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled, topical intranasal or intro-ocular steroids, and adrenal replacement doses <10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  • Prior organ transplantation, including allogeneic stem cell transplantation.
  • Patients who are receiving any other investigational agents
  • Pregnant or breast feeding. Women of childbearing potential must have a negative pregnancy test at screening. Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal. Post-menopause is defined as amenorrhea greater than or equal to 12 consecutive months. Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti- estrogens, ovarian suppression or any other reversible reason.
  • History of allergy to study drug components.
  • History of severe hypersensitivity reaction to any monoclonal antibody (Grade greater than or equal to 3 NCI-CTCAE v 5.0), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma).
  • Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstab1e angina, congestive heart fai1ure (greater than or equal to New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
  • Persisting toxicity related to prior therapy of Grade >1 NCI-CTCAE v 5.0; however, alopecia, sensory neuropathy Grade less than or equal to 2 or other Grade less than or equal to 2 AEs not constituting a safety risk based on investigator's judgment are acceptable.
  • Known alcohol or drug abuse.
  • Vaccination within 4 weeks of the first dose of M7824 and 4 weeks after the last dose of M7824 are prohibited.
  • HPV vaccination within one year of the first dose of M7824
  • Subjects with inherited bleeding disorders, a history of bleeding diathesis such as vWF deficiency, and participants on either active anti-platelet therapy or active anti-coagulant therapy until such time as more information becomes available that shows there is no increased risk for those populations.

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.